The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Tackling the clinical complexity of breast cancer
Lenti, M. V., Sottotetti, F., & Corazza, G. R. (2022) · Drugs in Context · doi:10.7573/dic.2022-2-3 · Cited by 11
Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
Torres-Jiménez, J., Esteban-Villarrubia, J., & Ferreiro, R. (2022) · Cancers · doi:10.3390/cancers14153718 · Cited by 11
Xu, H., Zhang, H., Guo, W. Q., Zhong, X. Z., Sun, J., Zhang, T., Wang, Z., & Ma, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10015-6 · Cited by 11
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
Li, J., Wang, X., Wang, S., Wang, S., Wang, T., Liu, Y., Geng, C., Jin, F., Yin, Y., Zhang, Q., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-48 · Cited by 12
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò, E., Repetto, M., Bielo, L. B., Tarantino, P., & Curigliano, G. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000629 · Cited by 11
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy
Gouda, M. A., & Subbiah, V. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000627 · Cited by 12
de Blanco, E. J. C., Addo, E. M., Rakotondraibe, H. L., Soejarto, D. D., & Kinghorn, A. D. (2023) · Natural Product Reports · doi:10.1039/d2np00080f · Cited by 11
Novel HER-2 Targeted Therapies in Breast Cancer
Fernandes, C. L., Silva, D., & Mesquita, A. (2023) · Cancers · doi:10.3390/cancers16010087 · Cited by 11
Grammoustianou, Μ., Dimitrakopoulos, F.-I. D., & Koutras, A. K. (2024) · Cancers · doi:10.3390/cancers16101801 · Cited by 13
Michel, L. L., Hartkopf, A. D., Fasching, P. A., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wallwiener, M., et al. (2020) · Cancers · doi:10.3390/cancers12103021 · Cited by 14
Young, J. R., Ressler, J. A., Mortimer, J. E., Schmolze, D. D., Fitzgibbons, M., & Chen, B. T. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109948 · Cited by 11
SABR in oligometastatic breast cancer: Current status and future directions
Stewart, R., White, M. A., Tan, J., Siva, S., Karroum, L., & David, S. (2021) · The Breast · doi:10.1016/j.breast.2021.10.009 · Cited by 11
Atiq, S. O., Hirshman, N. A., Shariff, A. I., & Zhang, T. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.10.002 · Cited by 11
Husna, S. M. N., & Wong, K. K. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.10.005 · Cited by 11
Antibody-drug conjugates as a targeted therapeutic approach across entities in oncology
Lordick, F., Merz, M., Büch, E. A. M., & Aigner, A. M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0093 · Cited by 11
Mastering the Use of Novel Anti-HER2 Treatment Options
Tarantino, P., Trapani, D., & Curigliano, G. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00216 · Cited by 11
Li, C. (2024) · American Journal of Cancer Research · doi:10.62347/emik7909 · Cited by 10
Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer
Qureshi, Z. A., Altaf, F., Jamil, A. R., Siddique, R., & Fatima, E. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001126 · Cited by 11
Xia, L.-Y., Cao, X., Hu, Q.-L., & Xu, W.-Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1413674 · Cited by 10
Camarda, F., Paderno, M., Cannizzaro, M. C., Nero, C., Sabatucci, I., Fucà, G., Musacchio, L., Salutari, V., Scambia, G., & Lorusso, D. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241277647 · Cited by 10
Manna, M., Brabant, M., Greene, R., Chamberlain, M. D., Kumar, A., Alimohamed, N. S., & Brezden‐Masley, C. (2024) · Current Oncology · doi:10.3390/curroncol31090422 · Cited by 10
Lazaratos, A.-M., Dankner, M., Hamouda, A., Labidi, S., Cohen, V., Panasci, L., Friedmann, J. E., Patenaude, F., Ferrario, C., Basik, M., et al. (2024) · Current Oncology · doi:10.3390/curroncol32010001 · Cited by 12
Management of nausea and vomiting induced by antibody–drug conjugates
Farhat, J., Sakai, H., & Tsurutani, J. (2025) · Breast Cancer · doi:10.1007/s12282-025-01670-1 · Cited by 10
Self-citationKo, H. C., Strickland, K. C., Jaggessarsingh, D., Dillard, A., Green, M. F., Newburn, E. N., Sellaro, T. L., Klein, J. L., Caveney, B. J., Eisenberg, M. T., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1565872 · Cited by 12
Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis
Pathak, N., Iorio, M. R. D., Gimenez, D. M., Berner-Wygoda, Y., Savill, J., Aljuhani, A., Mittal, A., Kumar, V., & Amir, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104787 · Cited by 11
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf
Alhazza, A., Oyegbesan, A., Bousoik, E., & Aliabadi, H. M. (2025) · Pharmaceuticals · doi:10.3390/ph18060895 · Cited by 12
The adverse event of interstitial lung disease in patients treated with antibody–drug conjugates
Fang, N., Wang, X., Xu, Q., Zhan, H., Wang, Y., Zhao, B., Huang, H. F., & Lin, M. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf228 · Cited by 10
Park, Y. H., Cortés, J., Modi, S., Hurvitz, S. A., Bianchini, G., Iwata, H., Shitara, K., Siena, S., Goto, Y., Ku, G. Y., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf396 · Cited by 10
Self-citationRehorst, P., & Kros, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114583 · Cited by 10
Tsurutani, J., Noguchi, K., & Tanabe, A. (2026) · Breast Cancer · doi:10.1007/s12282-025-01814-3 · Cited by 10
Self-citationCheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026) · Physiological Reviews · doi:10.1152/physrev.00039.2025 · Cited by 12
Novel targeted therapies and immunological strategies for breast cancer treatment
Mussa, A., Hamid, M. A. M., Talib, M., Ehinnou, I. B., Bragoli, A. J., Hajissa, K., Mokhtar, N. F., Mohamud, R., Al-Hatamleh, M. A. I., & Hassan, R. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117929 · Cited by 10
Mishra, A., Abelman, R. O., Cunneely, Q. E., Putaturo, V. R., Deshpande, A., Bell, R., Seider, E. M., Xu, K. H., Shan, M., Kelly, J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2601563123 · Cited by 10
Metabolic syndrome and breast cancer: a dangerous association for postmenopausal women.
Palmiero, P., Maiello, M. R., Cecere, A., & Ciccone, M. M. (2021) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v92i3.11335 · Cited by 10
Advances with antibody-drug conjugates in breast cancer treatment
Subhan, M. A., & Torchilin, V. P. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.016 · Cited by 10
Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles
Steindl, A., Brastianos, P. K., Preusser, M., & Berghoff, A. S. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab105 · Cited by 10
Bernat‐Peguera, A., Trigueros, M., Ferrando‐Díez, A., Ibáñez, C., Bystrup, S., Martínez‐Cardús, A., Vila, M. M., & Martinez‐Balibrea, E. (2022) · The Breast · doi:10.1016/j.breast.2022.01.007 · Cited by 10
Kalmuk, J., Rinder, D., Heltzel, C. E., & Lockhart, A. C. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2050692 · Cited by 10
Kang, M., Shin, J. I., Han, S., Kim, J. Y., Park, J., Kim, K. I., Kang, J. H., & Lee, T. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071338 · Cited by 10
Lin, C.-Y., Yu, C.-J., Shen, C., Liu, C., Chao, T., Huang, C., Tseng, L., & Lai, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01812-x · Cited by 10
HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis
Tincknell, G., Naveed, A., Nankervis, J., Mukhtiar, A., Piper, A., Becker, T. M., Chantrill, L. A., Aghmesheh, M., Vine, K. L., Ranson, M., et al. (2022) · Cancers · doi:10.3390/cancers14235754 · Cited by 10
Sun, W., Li, Y., Sui, D., Qi, Z., Zhao, X., Zhou, W., Hu, H., Liu, X., Song, Y., & Deng, Y. (2023) · Biomaterials Science · doi:10.1039/d2bm01769e · Cited by 10
Huang, X., Lin, D., Lin, S., Luo, S., Huang, X., Deng, Y., Weng, X., & Huang, P. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.03.013 · Cited by 10
Targeting human EGFR 2 (HER2) in salivary gland carcinoma
Wotman, M. T., El‐Naggar, A. K., & Ferrarotto, R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2208350 · Cited by 10
Nerone, M., Rossi, L. A., Condorelli, R., Ratti, V., Conforti, F., Palazzo, A., & Graffeo, R. (2023) · Cancers · doi:10.3390/cancers15133305 · Cited by 10
Wang, L., Hong, R., Shi, S., Wang, S., Chen, Y., Han, C., Li, M., & Ye, F. (2024) · BMC Cancer · doi:10.1186/s12885-024-12818-1 · Cited by 10
Marquez, J., Dong, J., Dong, C., Tian, C., & Serrero, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246197 · Cited by 10
Jackisch, C., Barcenas, C. H., Bartsch, R., Palma, J. D., Glück, S., Harbeck, N., Macedo, G., O’Shaughnessy, J., Pistilli, B., Ruíz‐Borrego, M., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.02.001 · Cited by 10
The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications
Roman, B. I. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00294 · Cited by 10
Heterogeneous HER2 Amplification—a New Clinical Category of HER2-Positive Breast Cancer?
Okines, A. F. C., & Turner, N. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0936 · Cited by 10
Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Saito, M., Mizuno, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2022) · Oncology Reports · doi:10.3892/or.2022.8366 · Cited by 10
Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets
Santa-Maria, C. A., & Wolff, A. C. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.02217 · Cited by 10
Can we define breast cancer HER2 status by liquid biopsy?
Cosimo, S. D., Marco, C. D., Silvestri, M., Busico, A., Vingiani, A., Pruneri, G., & Cappelletti, V. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.003 · Cited by 9
Liu, M., Xiang, Q., Dai, F., Yuan, Y., Wu, Z., & Xiang, T. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.05.001 · Cited by 9
Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies
Chan, K. L., Faiz, S. A., Altan, M., & Sheshadri, A. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-12 · Cited by 9
Cardiac toxicity of HER-2 targeting antibody–drug conjugates: overview and clinical implications
Zalaquett, Z., Hachem, M. C. R., Assi, A., Mohanna, R., Farhat, M., Noujaim, C., & Kourié, H. R. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407756 · Cited by 10
Seban, R., Champion, L., Moura, A. D., Lerebours, F., Loirat, D., Pierga, J., Djerroudi, L., Genevée, T., Huchet, V., Jehanno, N., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06929-x · Cited by 9
Yang, E., D’Alfonso, T. M., Morrow, M., Brogi, E., & Wen, H. Y. (2024) · Histopathology · doi:10.1111/his.15346 · Cited by 9
Perioperative Treatment in Gastric Cancer: A Fast-Changing Field
Costa, M., Fernandes, C. L., & Magalhães, H. (2024) · Cancers · doi:10.3390/cancers16234036 · Cited by 9
Fountzilas, E., Karageorgopoulou, S., Karakatsoulis, G., Tryfonopoulos, D. J., Papazisis, K., Koutras, A. K., Koumarianou, A. A., Zafeiri, G. C. M., Biziota, E., Nikolaidi, A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100095 · Cited by 9
Huang, R., Hu, A., Rong, Q., Shu, D., Chen, M., Yang, W., Zhang, Y., Zheng, Q., An, X., Xue, C., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06082-5 · Cited by 9
Nanopore-based random genomic sampling for intraoperative molecular diagnosis
Emiliani, F. E., Ismail, A. A. O., Hughes, E. G., Tsongalis, G. J., Zanazzi, G. J., & Lin, C. (2025) · Genome Medicine · doi:10.1186/s13073-025-01427-7 · Cited by 12
A Site-Specific MiniAp4–Trastuzumab Conjugate Prevents Brain Metastasis
Masmudi‐Martín, M., Oller‐Salvia, B., Perea, M., Teixidò, M., Valiente, M., Giralt, E., & Sánchez‐Navarro, M. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01091 · Cited by 9
Cancer-targeting drug conjugates drives a new era in precise cancer treatment
Deng, J., Shi, J., Li, D., Jiao, X., Liu, J., Tian, H., Liu, N., Luo, C., Kamei, K., & Tian, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110960 · Cited by 9
Thill, M., Janni, W., Albert, U., Banys‐Paluchowski, M., Bartsch, R., Bauerfeind, I., Bjelic-Radisic, V., Blohmer, J., Budach, W., Dall, P., et al. (2025) · Breast Care · doi:10.1159/000545018 · Cited by 9
Proximity-induced membrane protein degradation for cancer therapies
Zhang, D., Wang, Z., Inuzuka, H., & Wei, W. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00141b · Cited by 9
Tibau, A., Cliff, E. R. S., Romano, A., Borrell, M., Moltó, C., & Kesselheim, A. S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103088 · Cited by 9
Wang, Z., Zhu, J., Sang, L., Tang, L., Zhang, S., Tan, Y., Zhao, Y., & Hao, K. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107234 · Cited by 9
Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates
Duhon, A. A., & McLean, K. (2025) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2502040017 · Cited by 9
Alanazi, A. S., Alanazi, A. A., Alanizi, A. H., Babalghaith, R., Alotaibi, R., Alnuhait, M. A., & Bakhribah, H. (2025) · Current Oncology · doi:10.3390/curroncol32100575 · Cited by 9
Rao, M., Wu, L., Chen, H., Wu, X., Wang, H., Chen, Y., & Chen, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334513 · Cited by 9
Caught in the crossfire: cardiac complications of cancer therapy
Guerra, G., Mergiotti, M., Ardehali, H., Hirsch, E., & Ghigo, A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci198289 · Cited by 9
Yao, H., Yan, M., Tong, Z., Wu, X., Yin, Y., Ryu, M., Park, J., Jiang, S., Kim, J. H., Wang, S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02612-9 · Cited by 10
Self-citationAntibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions
Cheng, B., Gong, L., Wang, Z. P., Peng, P., Xu, K., Huang, H., & Wu, P. (2026) · MedComm · doi:10.1002/mco2.70699 · Cited by 9
Schmid, P., Im, S., Nowecki, Z., Wysocki, P. J., Jassem, J., Jung, K. H., Lord, S., Armstrong, J. M., Stewart, R. A., Vuković, P., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01181-8 · Cited by 9
Self-citationRole of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
Lengyel, C. G., Habeeb, B. S., Khan, S. Z., Bairi, K. E., Altuna, S. C., Hussain, S., Mazher, S. A., Trapani, D., & Petrillo, A. (2020) · Gastrointestinal Disorders · doi:10.3390/gidisord3010001 · Cited by 9
DeBusk, K. P. A., Abeysinghe, S., Vickers, A. D., Nangia, A., Bell, J. A., Ike, C., Forero, A., & Blahna, M. T. (2021) · Future Oncology · doi:10.2217/fon-2021-0742 · Cited by 10
Li, F., Ju, Q., Gao, C., Li, J., Wang, X., Yan, M., Zhang, L., Huang, M., Long, Q., Jin, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819818 · Cited by 10
Self-citationChianca, M., L’Abbate, S., Fabiani, I., Aimo, A., Emdin, M., Passino, C., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2197589 · Cited by 10
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors
LaRose, M., Connolly, R. M., O'Sullivan, C. C., Velcheti, V., Vilimas, R. J., Gano, K., Bates, S. E., Pommier, Y. G., & Thomas, A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad023 · Cited by 9
Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
Zhang, W., Li, E., Wang, L. H.-C., Lehmann, B. D., & Chen, X. S. (2023) · Cancers · doi:10.3390/cancers15082194 · Cited by 9
Habara, H., Okamoto, H., Nagai, Y., Oitate, M., Takakusa, H., & Watanabe, N. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2371 · Cited by 9
Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
de Weger, V. A., Schutte, T., Konings, I. R. H. M., & van Oordt, C. W. M. D. H. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e38 · Cited by 9
Guidi, L., Valenza, C., Trapani, D., & Curigliano, G. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2277915 · Cited by 9
Remodeling the cellular stress response for enhanced genetic code expansion in mammalian cells
Sushkin, M. E., Koehler, C., & Lemke, E. A. (2023) · Nature Communications · doi:10.1038/s41467-023-42689-2 · Cited by 9
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Verschoor, N., Smid, M., Jager, A., Sleijfer, S., Wilting, S. M., & Martens, J. W. M. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01743-z · Cited by 9
Ibrahim, R., Khoury, R., Ibrahim, T., Cesne, A. L., & Assi, T. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104265 · Cited by 10
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Saltalamacchia, G., Torrisi, R., Sanctis, R. D., Masci, G., Miggiano, C., Gaudio, M., Benvenuti, C., Jacobs, F., Gerosa, R., Santoro, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030500 · Cited by 9
Connolly, R. M., Wang, V., Hyman, D. M., Grivas, P. D., Mitchell, E. P., Wright, J., Sharon, E., Gray, R. J., McShane, L. M., Rubinstein, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0633 · Cited by 10
Jacobs, S. A., Wang, Y., Abraham, J., Feng, H., Montero, A. J., Lipchik, C., Finnigan, M., Jankowitz, R. C., Salkeni, M. A., Maley, S. K., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01823-8 · Cited by 9
Bender, L., CHOUAID, C., Moinard‐Butot, F., Barbe-Richaud, J.-B., Greillier, L., & Schött, R. (2024) · BioDrugs · doi:10.1007/s40259-024-00660-7 · Cited by 9
Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases
Pan, S. S., Gadrey, J. Y., Sammons, S. L., Lin, N., Tolaney, S. M., Tarantino, P., & Schlam, I. M. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241292266 · Cited by 9
Nakayama, T., Yoshinami, T., Yasojima, H., Kittaka, N., Takahashi, M., Ohtani, S., Kim, S. J., Kurakami, H., Yamamoto, N., Yamada, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08504-1 · Cited by 9
Self-citationWang, T., Zhang, Y., He, Y., Liu, Y., & Qi, P. (2021) · BioMed Research International · doi:10.1155/2021/5575286 · Cited by 9
Díaz-Gil, L., Brasó‐Maristany, F., Locatelli, C., Centa, A., Győrffy, B., Ocaña, A., Prat, A., & Pandiella, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02098-z · Cited by 9
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Salkeni, M. A., Rizvi, W., Hein, K. Z., & Higa, G. M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s288344 · Cited by 9
McAndrew, N. P. (2021) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000762 · Cited by 9
Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer
Du, Y., Miao, Z., Qiu, L., Lv, Y., Wang, K., & Guo, L. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/9578788 · Cited by 9
RetractedShukla, N., Chiang, R. S., & Colevas, A. D. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7089 · Cited by 9
Chi, Y., Shang, M., Xu, L., Gong, H., Tao, R., Song, L., Zhang, B., Yin, S., Cong, B., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811919 · Cited by 9
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
